- Home
- INDP vs EZRA Comparison
INDP vs EZRA Comparison
Compare INDP & EZRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$2.06
Company Overview
Basic Information| Metric | INDP | EZRA |
|---|---|---|
| Founded | 2000 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Specialty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5M | 4.2M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | INDP | EZRA |
|---|---|---|
| Price | $2.06 | $0.31 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 24.9K | ★ 28.3M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 12.02 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.27 | $0.15 |
| 52 Week High | $13.24 | $0.38 |
Technical Indicators
Market Signals| Indicator | INDP | EZRA |
|---|---|---|
| Relative Strength Index (RSI) | 49.06 | 67.25 |
| Support Level | $1.92 | $0.16 |
| Resistance Level | $3.19 | N/A |
| Average True Range (ATR) | 0.19 | 0.06 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 81.07 | 68.54 |
Price Performance
Historical Comparison INDP
EZRA
About INDP Indaptus Therapeutics Inc.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.